Comprehensive therapeutic solutions across major disease areas
Targeted therapies and immunotherapies transforming cancer care.
Novel tyrosine kinase inhibitor for EGFR-mutant non-small cell lung cancer. Phase III trial completed with promising PFS data.
Phase IIIAnti-PD-L1 monoclonal antibody for advanced melanoma and renal cell carcinoma. Breakthrough therapy designation from FDA.
ApprovedInvestigational PARP inhibitor for BRCA-mutated ovarian and breast cancers. Currently in Phase II trials across 15 centers.
Phase IICardiovascular treatments addressing the world's leading cause of death.
Fixed-dose combination antihypertensive with superior adherence rates. First-line therapy for essential hypertension.
ApprovedNext-generation statin with improved LDL-C reduction and favorable safety profile. Marketed in 20+ countries.
ApprovedNovel oral anticoagulant for stroke prevention in atrial fibrillation. Recently FDA approved (March 2026).
ApprovedInnovative therapies for central nervous system disorders.
Extended-release antiepileptic with once-daily dosing. Proven efficacy in focal onset seizures with favorable tolerability.
ApprovedOral CGRP receptor antagonist for acute migraine treatment. Phase III results show rapid onset and sustained pain relief.
Phase IIINovel dopamine agonist with reduced dyskinesia risk. Currently enrolling patients for Phase II study.
Phase IICombating antimicrobial resistance and emerging infectious threats.
Broad-spectrum antibiotic with activity against MRSA and ESBL-producing organisms. Reserved for hospital-acquired infections.
ApprovedOral antiviral with broad-spectrum activity against respiratory viruses including influenza and RSV. Phase II data expected Q4 2026.
Phase IINovel adjuvant platform enhancing immune response in vulnerable populations. Partnered with global health organizations.
PreclinicalNovel adjuvant formulation for enhanced vaccine immunogenicity. IND filing expected Q2 2027.
AAV-based gene therapy for inherited retinal dystrophies. First-in-human study underway.
Both programs actively enrolling patients across multiple global trial sites.
Late-stage trials with potential NDA submissions in 2027.
Approved and available in markets across North America, Europe, and Asia.